Background: Probiotic functional foods are widely advertised to consumers primarily based on probiotic supplements. Objective: Determine if consumption of yogurt containing a high dose of probiotics improves health in children ages 1-3 years attending daycare/school centers. Subjects/Methods: Double-blinded, randomized, placebo-controlled, allocation concealment clinical trial. Setting: Outpatient participants in the Washington, DC area. Participants: 182 healthy children between the age of 1 and 3 years attending daycare/ school at least 3 days a week. Intervention: Active was a strawberry yogurt-based drink supplemented with Bifidobacterium animalis ssp. lactis (B. lactis) BB-12. The placebo was indistinguishable from the active drink, differing only in absence of the probiotic BB-12. Primary objective was to determine if consumption of a probiotic-containing yogurt-based drink decreases absences due to illnesses from daycare for children ages 1-3 years. Secondary was to determine if probiotic-containing yogurtbased drink improves overall parental satisfaction due to decreased absences from work and an overall healthier child. Results: There were no significant differences in the days of missed school per group, with 51.9% in the active group and 47.1% in the placebo group missing at least 1 day of school throughout the study. Additionally, there were no differences in any secondary outcomes among the groups. Conclusions: Consumption of a yogurt-based drink delivering 10 10 CFU of Bifidobacterium animalis ssp. lactis (B. lactis) BB-12 per day did not decrease the number of days missed of school due to an illness. Additional independent research on the potential of BB-12 to reduce illness in children needs to be conducted.
Introduction
Probiotics are live microorganisms, which when administered in adequate amounts confer a health benefit on the host (Food and Agriculture Organization, 2001) . Previous studies in pediatric populations have shown positive benefits of probiotics, such as reducing the incidence and severity of necrotizing enterocolitis (Alfaleh and Bassler, 2008) , a reduction in antibiotic associated diarrhea (Vanderhoof et al., 2000) , reducing the duration of acute diarrhea (Rosenfeldt et al., 2002) and in the prevention of early atopic disease in children (Kalliomaki et al., 2001) . However, almost all probiotic studies have been conducted outside of the United States, in very different settings than probiotics are generally consumed in the US.
Children who attend daycare have been found to have a significantly increased risk of ear infections and upper respiratory infections than those who do not attend daycare (Fleming et al., 1987) . Because of policies at daycares which require children who are sick to stay at home, illnesses have costly economic affects on families and in turn loss of revenue and productivity for businesses (Haskins, 1989) . If consumption of a probiotic in these settings would decrease acute illness this could significantly impact children, parents and businesses.
There is a need for controlled clinical studies on specific probiotic strains, in settings and modalities that are similar to how probiotics are consumed and used in the U.S. (Pedone et al., 1999; Hatakka et al., 2001; Weizman et al., 2005; Lin et al., 2009) . Our previous studies have found that by providing an intervention in the form of a yogurt drink we greatly increase compliance, and present parents with a simple alternative to traditional probiotic supplemental pills or capsules (Merenstein et al., 2009) . Moreover, as yogurt is known to be a nutrient-dense food, a yogurt supplemented with additional probiotics is likely to be more appealing to parents for their children's long-term consumption than probiotic supplements.
Thus, the overall goal of this study was to determine if daily consumption of a probiotic-supplemented yogurtbased beverage containing Bifidobacterium lactis BB-12 (BB-12) at a minimum 10 10 colony forming units (CFU)/per serving can reduce daycare absences.
Subjects and methods

Study design
A double-blinded, randomized, placebo-controlled, patientoriented trial was conducted. Participants consumed 4 ounces of active or control drink for 90 consecutive days and data were collected via regularly scheduled phone calls. The Georgetown University IRB, in Washington, DC, approved all aspects of the trial and participants' parents signed informed consent. An independent Data and Safety Monitoring Board (DSMB) met and reviewed data at 25, 50 and 75% completion and reviewed all adverse events. When deciding what probiotic microorganism to study we examined many possibilities. The ability to isolate an orally administered probiotic in the stools is considered to be a good indicator that the strain is able to reach key target sites throughout the intestinal tract. The ability of BB-12 to survive intestinal transit has been documented in several studies (Fukushima et al., 1997; Malinen et al., 2002; Ouwehand et al., 2004; Bartosch et al., 2005) . The majority of prior research on BB12 has focused on the probiotics role in regulating digestive health, however a few promising studies have found a role for BB12 in the immune system, by demonstrating an improvement in eczema, significant increase in total IgA and anti-poliovirus IgA (Fukushima et al., 1998; Isolauri et al., 2000) . Because of these reasons and the wide usage of BB12 in commercial products we considered it an appropriate strain to study.
In addition to phone interviews, parents kept daily diaries. Diary data were used for secondary assessment and compared to phone data collection calls. All data were double entered.
Participants
Healthy children between the age of 1 and 3 years attending daycare center/school at least 3 days a week in the Washington, DC area were recruited into the study. Exclusion criteria were: taking any regular medication at initiation of study, lactose intolerance, allergy to strawberry, inability of a parent to speak English or Spanish, active infection, diarrhea, congenital anomalies or chronic disease. Participants were also excluded if they were being breastfed or if they refused to stop eating or drinking other probiotics during the course of the study.
Randomization
The randomization scheme was generated using Stata software by data managers who were excluded from participant contact (StataCorp, 2005) Households were randomized in a 1:1 ratio to receive either the active or control drink. Stratified block randomization was implemented. Children in the same household were assigned to the same drink group. Once eligibility criteria were met, the participant was randomized to one of the two groups, study identification was generated and group assigned.
Interventions
Both placebo and the active intervention were strawberryflavored dairy drinks developed at Pennsylvania State University. The drinks were developed for the study although the active drink is currently available commercially on campus at The Berkey Creamery at Penn State in State College, Pennsylvania. Both drinks combined a commercial blend Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus. Control and active drink were identical except that prior to packaging the active drink was supplemented with the probiotic BB-12, acquired from Chr. Hansen (Milwaukee, Wisconsin). Subjects were provided 4 fluid ounces (112 grams) per day of either drink. To verify the viable count of probiotic in the system, product was analyzed weekly by pour plating suitable dilutions on selective MRS agar followed by anaerobic incubation at 37 1C for 48 h. Random colonies counted as B. animalis ssp. lactis were picked and identified by PCR using subspecies specific primers (Ventura et al., 2001) .
Blinding
The appearance, taste, nutritional composition (proteins, carbohydrates, lipids and energy) and packaging (1-quart bottles) of the active and control products were identical to ensure that neither subjects, their parents, or researchers knew the identity of the study samples. Study personnel, including clinicians, research assistants and office personnel, were naive to which treatment these labels represented. Dr Roberts and the PSU dairy plant were not blinded to product identity and assigned labels but did not have contact with participants. All of these measures led to successful true allocation concealment and proper blinding.
Outcome measures
The study was designed for one primary outcome: missed days of school due to illness. To assess this outcome, parents were specifically asked during the bi-weekly phone call, 'How many days of daycare/school did your child's school have and how much was missed in the past two weeks due to them not feeling well, if any?' Parents were also asked to record these data in their daily diaries.
Secondary outcomes per group included: presence of diarrhea; amount of yogurt consumed on a daily basis; consistency of stools; presence of respiratory infection; missed parental work; doctor visits; illnesses; and overall parental satisfaction.
Adverse events (AEs) were collected at all regularly scheduled phone calls and in the interim parents were provided a 24-h phone number for immediate reporting. Parents, participant's primary doctor and the PI determined if AEs were associated with drinks. Serious AEs (SAEs) were defined as any incidences of death, life-threatening event, hospitalization, prolongation of hospital stay, or event resulting in permanent disability.
Statistical analysis
The sample size calculation is based on the primary outcome variable, days of absence from day care. Assuming that consuming BB-12 yogurt would result in a 20% reduction in absences, a Type I error of 0.05 is postulated, with a power of 80%. A previous study reported a mean (standard deviation, s.d.) of 5.8 (4.5) days of illnesses among Finnish children aged one to six years, during a seven-month follow up (Hatakka et al., 2001) . However, stricter US daycare regulations and a younger age in our study led us to anticipate higher rates of illness-associated daycare absences. We anticipated children in our study wound miss about 1 in 6 days of day care or slightly more than 10 days over a three month period. Using this estimate of the mean and the estimate of 4.5 for the s.d. from the Finnish study, the estimated minimum sample size without dropout is 74 to detect a 20% reduction in absences.
Statisticians blinded to the group allocation conducted statistical analyses. Furthermore, all research personnel were blinded while examining initial data. Baseline demographics were compared between the groups using independent t-test for continuous variables and chi-square test for categorical variables. All analyses of primary and secondary outcomes were conducted on an intention-to-treat (ITT) basis. Incidence rate ratios were calculated using the number of events divided by number of days in study. A P-value of less than 0.05 was considered to indicate statistical significance. All P-values were two-sided. Intercooled Stata 9.2 for Windows was used to run the analyses (StataCorp, 2005) .
Results
Active drink
Viable counts of B. animalis ssp. lactis and pH of the probiotic-containing yogurt-based beverage were evaluated over 60 days of incubation at 4 1C. Data presented in Figure 1 demonstrate that although the population of viable BB12 in the product declined over time, the yogurt-drink delivered at least 1 Â 10 10 cfu/100 ml serving of BB-12 at the end of its 30-day shelf life. The data suggests the useful shelf-life could be extended beyond 30 days and in fact the product taste tested well for 50 days. The relatively constant pH seen in Figure 1 indicates limited post manufacture acidification again suggesting the shelf life could be extended beyond 30 days.
Recruitment, enrollment and participant flow During enrollment period from September 12th 2007 to June 9th 2008, 268 participants left voice messages stating interest in the study, Figure 2 . We were able to screen 233 of these participants. Thirty-six were screened not eligible for the study. One hundred eighty-two participants were enrolled or 68% of participants who left messages on the recruitment line. The active participant group had 87 participants and the control group 95.
Baseline demographics
Randomization worked appropriately in that there were no significant differences in the baseline characteristics between the two groups, Table 1 . There were a total of 163 families Figure 1 BB-12 manufacturing data over time.
The SIPPY Study DJ Merenstein et al represented in the study. The majority of the participants in both groups were self-reported by their care-givers as being white and living in a household with the annual income over $100 000. However over 10% of the participants had at least one parent of Hispanic descent, with. 10% of the interviews being conducted in Spanish (data not shown).
Compliance
Compliance is defined in a two step fashion. First, between each interview (a 14 day period), a child was defined as compliant if they consumed a one-half or more of a drink 70% (10/14) of the days. Second, overall compliance was defined as being compliant 70% of the study periods (usually 5 or more out of 7 periods). The difference in compliance between the active group (77%) and the placebo group (74%) was not significant (P ¼ 0.691). Those participants who thought they were in the active group were significantly more complaint than those who thought they were in the placebo group (P ¼ 0.01). However there was no association between believing one's child was in the active group and actually being in the active group (P ¼ 0.633).
Primary outcomes
The primary outcome, missed days of school due to illness per 100 days, was similar in both the active (2.82 days absent/100 school days) and control (2.51 days absent/100 school days) (P ¼ 0.374), Table 2 .
Secondary outcomes
There were also no significant differences among the secondary outcomes measured in the study, Table 2 . Parents in the control group reported 2.74 days affected/100 days of the participants in the control group had a change in activity due to illness, versus 3.84 days affected/100 days in the active group (P ¼ 0.172). Runny nose was the most common symptom, with rates of 13.41 days affected/100 days reported in the control group and 16.5 days affected/100 days in the active group. The rate of diarrhea was low and consistent amongst the two groups with 1.06 days affected/ 100 days in the control group and 1.19 days affected/100 days in the active group.
Adverse events
Six total adverse events were reported for the study, three in each group, involving 5 study subjects, Table 3 . One subject had both diarrhea and dermatitis at the same time. This participant was in the active group. There were no serious adverse events (SAEs) in either group reported throughout the entire study.
Discussion
The probiotic-containing yogurt-based beverage we studied did not decrease absences due to illnesses in daycare/school for healthy children ages 1-3 years. The SIPPY Study DJ Merenstein et al no differences among the groups in any secondary outcomes. It is reported that more than half of all young children attend daycare centers in the United States (Shonkoff, 2003; Silverstein et al., 2003) . Absences due to illnesses are costly both at the individual and the societal level and these absences are generally due to diarrhea or upper respiratory infections. Unfortunately the strain of probiotic we studied did not show any positive impact on absences.
One is left to wonder why we did not find any differences in daycare absences while previous research with different probiotic products has found differences. A study by Hatakka et al. enrolled 571 healthy children ages one to six years from daycare centers in Helsinki Finland and followed them for seven months. Treatment consisted of 200 ml per day of 5-10 Â 10 5 CFU/ml of Lactobacillus rhamnosus GG (LGG, 1-2 Â 10 8 /day), with the daycare centers dispensing the supplements five days per week. Children in the LGG group had a 16% decrease in absences from daycare, and a significantly lower incidence of respiratory infection (relative reduction 17%, absolute reduction 9%). In addition, fewer children in the LGG group were prescribed antibiotics for respiratory infections, a relative reduction of 19% (absolute reduction 10%) (Hatakka et al., 2001) . Another long-term study was conducted by Weizman et al. for 201 healthy term children between the ages of four to ten months at 14 daycare centers in Southern Israel. Children were solely fed for 12 weeks with one of three treatments, a formula fortified with either 1.2 Â 10 9 CFU/day of BB-12, or L. reuteri ATCC 55730, or placebo formula containing no added probiotic. The control group had more days of febrile illness, increased episodes of diarrhea and increased absences from daycare than either group on the probiotic-fortified formulas (Weizman et al., 2005) . Both of these studies were conducted outside of the US using different probiotic bacteria and in different settings than children in the U.S. generally consume probiotics. In the Hatakka study the children were fed probiotic milk by daycare workers and in the Weizman study the participants were solely formula fed with the different interventions. We were interested in a study that resembled how children in the U.S. consume drinks, stored in home refrigerators and consumed without study personnel observation. Although, we had high compliance compared to traditional medicines, compliance could not compare to such structured studies. Two recent studies conducted in Asia also found positive results; however, the populations studied were different from those generally targeted by probiotic companies. Lin et al. conducting a study in Taiwan, found some positive reduction in illness in preschool children with a variety of probiotic supplements (Lin et al., 2009) . However this study greatly differed from ours in that the participants consumed capsules for 7 months, the study was not conducted by recognized CONSORT guidelines, and a multitude of different strains were studied at once. Another study by Leyer et al. in China using 2 different probiotics supplied to children as dry powder also found reduction in acute illness (Leyer et al., 2009) . In contrast to our study the manufacturer of the probiotics sponsored, conducted and published the study.
There are many other potential reasons the BB-12-fortified yogurt and routine yogurt had no differences in outcomes. We anticipated much higher rates of illness and missed school. It is possible that our population was too healthy at baseline, as on a scale of 1 to 10 with 1 ¼ very unhealthy and 10 ¼ extremely healthy, our placebo group reported baseline health of 8.9 and our active group 9.0. Additionally, it is possible we didn't see the high rates of illness we anticipated because both the regular and fortified yogurt improved health, as overall rates of illness and absences were lower than historical cohorts. Finally, it is possible that BB-12, although promising in other patient oriented outcomes, has no impact on reducing daycare absences. In fact, Weizman et al. reported that formula containing BB-12 did not reduce absence rates, whereas formula with L. reuteri ATCC 55730 did. We do believe there were three important outcomes from our study. First, we showed that it is possible to produce a yogurt containing a high concentration of BB-12 which remains viable at target levels for well over one month. Second, we found that the majority of children consistently consumed the drink, an important factor in effective delivery of efficacious probiotics. Finally, perhaps most importantly there were very few adverse events reported in this study; only 6 minor self-limited events were reported with over 12 000 days of product consumption.
Our study has several limitations that need to be noted. It is possible that our study was negative because our choice of probiotic has a limited ability to reduce daycare absences in young children. We intentionally did not include independent examinations of children by physicians and instead relied on parental report. We studied a functional food, not a medicinal product; since parents will feed their children without physician input, we felt it was best to assess it under similar conditions. A limitation of this method is that these assessments are subjective and vary by evaluator. Also compliance was measured by self report. However, we analyzed using intention to treat, which is especially appropriate for a food product which is unlikely to be consumed in real life situations without missed servings. Also we only followed the participants during one winter, which happened to be a very mild winter in the DC area. Finally, our population tended to be of high socioeconomic status, only 2 participants had no health insurance. This clearly limits some generalization that can be drawn from our study; however this is often the group that is targeted to purchase these products.
Our randomized clinical trial showed that BB-12 fortified yogurt is safe and well tolerated for children 1-3 years old but did not reduce illnesses and daycare absences. We are currently conducting further investigations employing the drink in different settings and with different patient populations. We believe it is crucially important that other probiotic products on the market are tested independently and in patient-oriented settings. The need for well-designed, objective studies which assess patient-oriented efficacy and safety outcomes is tremendously important in the field of probiotics, especially considering the plethora of products being advertised and sold in the marketplace. Although this study does not support the value of this probiotic yogurt at reducing absence from day care, it does substantiate the product was well-tolerated, viable counts remained at high levels for a long period of time and that compliance is extremely high with this mode of ingestion.
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